The personalised medicine technology provider hiked its overall funding to $115m, with Cardinal Health, McKesson Ventures and Novartis all backing a series C extension.

Healthcare services provider Cardinal Health led the $33m second tranche of a series C round for Vineti, the US-based operator of a personalised medicine management product, on Tuesday that now totals $68m. McKesson Ventures, the investment arm of pharmaceutical distributor McKesson, also took part in the round, as did pharmaceutical firm Novartis, Canaan Partners, Threshold…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.